Tocilizumab in patients with severe COVID-19: a retrospective cohort study G Guaraldi, M Meschiari, A Cozzi-Lepri, J Milic, R Tonelli, M Menozzi, ... The Lancet Rheumatology 2 (8), e474-e484, 2020 | 1035 | 2020 |
Discontinuation of maintenance therapy for cryptococcal meningitis in patients with AIDS treated with highly active antiretroviral therapy: an international observational study C Mussini, P Pezzotti, JM Miró, E Martinez, JCLB de Quiros, P Cinque, ... Clinical infectious diseases 38 (4), 565-571, 2004 | 160 | 2004 |
Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome A Cossarizza, C Mussini, N Mongiardo, V Borghi, A Sabbatini, ... Aids 11 (1), 19-26, 1997 | 156 | 1997 |
Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital A Bedini, C Venturelli, C Mussini, G Guaraldi, M Codeluppi, V Borghi, ... Clinical microbiology and infection 12 (1), 75-80, 2006 | 151 | 2006 |
Discontinuation of Primary Prophylaxis for Pneumocystis carinii Pneumonia and Toxoplasmic Encephalitis in Human Immunodeficiency Virus Type I—Infected … C Mussini, P Pezzotti, A Govoni, V Borghi, A Antinori, AA Monforte, ... The Journal of infectious diseases 181 (5), 1635-1642, 2000 | 140 | 2000 |
A novel methodology for large-scale phylogeny partition MCF Prosperi, M Ciccozzi, I Fanti, F Saladini, M Pecorari, V Borghi, ... Nature communications 2 (1), 321, 2011 | 138 | 2011 |
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients M Nasi, V Borghi, M Pinti, C Bellodi, E Lugli, S Maffei, L Troiano, ... Aids 17 (11), 1696-1698, 2003 | 115 | 2003 |
Rhodococcus equi infection in HIV-positive subjects: a retrospective analysis of 24 cases M Arlotti, G Zoboli, GL Moscatelli, G Magnani, R Maserati, V Borghi, ... Scandinavian journal of infectious diseases 28 (5), 463-467, 1996 | 113 | 1996 |
Increased plasma levels of extracellular mitochondrial DNA during HIV infection: a new role for mitochondrial damage-associated molecular patterns during inflammation A Cossarizza, M Pinti, M Nasi, L Gibellini, S Manzini, E Roat, S De Biasi, ... Mitochondrion 11 (5), 750-755, 2011 | 109 | 2011 |
Late presenters in an HIV surveillance system in Italy during the period 1992-2006 V Borghi, E Girardi, S Bellelli, C Angeletti, C Mussini, K Porter, R Esposito JAIDS Journal of Acquired Immune Deficiency Syndromes 49 (3), 282-286, 2008 | 102 | 2008 |
Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver international 37 (4), 514-528, 2017 | 99 | 2017 |
Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study RK Lodwick, CA Sabin, K Porter, B Ledergerber, A Van Sighem, ... The Lancet 376 (9738), 340-345, 2010 | 97 | 2010 |
Evaluation of the Abbott Real-Time HIV-1 quantitative assay with dried blood spot specimens A Marconi, M Balestrieri, G Comastri, FR Pulvirenti, W Gennari, ... Clinical microbiology and infection 15 (1), 93-97, 2009 | 93 | 2009 |
Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study G Guaraldi, G Orlando, D De Fazio, ID Lorenzi, A Rottino, GD Santis, ... Antiviral therapy 10 (6), 753-759, 2005 | 93 | 2005 |
Patients presenting with AIDS in the HAART era: a collaborative cohort analysis C Mussini, C Manzardo, M Johnson, AA Monforte, C Uberti-Foppa, ... AIDs 22 (18), 2461-2469, 2008 | 88 | 2008 |
Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome A Cossarizza, C Ortolani, C Mussini, V Borghi, G Guaraldi, N Mongiardo, ... Journal of Infectious Diseases 172 (1), 105-112, 1995 | 84 | 1995 |
Impact of the M184V resistance mutation on virological efficacy and durability of lamivudine-based dual antiretroviral regimens as maintenance therapy in individuals with … R Gagliardini, A Ciccullo, A Borghetti, F Maggiolo, D Bartolozzi, V Borghi, ... Open forum infectious diseases 5 (6), ofy113, 2018 | 77 | 2018 |
Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study C Mussini, M Pinti, R Bugarini, V Borghi, M Nasi, E Nemes, L Troiano, ... Aids 19 (15), 1627-1633, 2005 | 72 | 2005 |
Features of ‘CD4-exploders', HIV-positive patients with an optimal immune reconstitution after potent antiretroviral therapy C Mussini, M Pinti, V Borghi, M Nasi, G Amorico, E Monterastelli, L Moretti, ... Aids 16 (12), 1609-1616, 2002 | 66 | 2002 |
Cytotoxic granule release dominates gag-specific CD4+ T-cell response in different phases of HIV infection E Nemes, L Bertoncelli, E Lugli, M Pinti, M Nasi, L Manzini, S Manzini, ... Aids 24 (7), 947-957, 2010 | 64 | 2010 |